<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
[ ]
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) July 11, 2000
-------------
-----------------
ANTEX BIOLOGICS INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 0-20988 52-1563899
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
</TABLE>
<TABLE>
<S> <C>
300 PROFESSIONAL DRIVE
GAITHERSBURG, MARYLAND 20879
(Address of principal executive offices) (Zip Code)
</TABLE>
Registrant's telephone number, including area code: (301) 590-0129
---------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE> 2
ITEM 4. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANTS
The Company has engaged Richard A. Eisner & Company, LLP as its
independent accountants for calendar year 2000.
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Antex Biologics Inc.
----------------------
(Registrant)
/S/GREGORY C. ZAKARIAN
--------------------------
Name: Gregory C. Zakarian
Title: Vice President, Finance
July 11, 2000
-------------
(Date)
